Facebook tracking pixel

Coming Soon

S10.AI's Next-Generation Telehealth Platform

C64.9
ICD-10-CM
Malignant Neoplasm of Kidney

Find comprehensive information on Malignant Neoplasm of Kidney, including clinical documentation, medical coding, ICD-10 codes C64, C65, and related SNOMED CT codes. This resource covers renal cell carcinoma, kidney cancer staging, treatment options, and best practices for healthcare professionals involved in diagnosis, coding, and patient care. Learn about relevant medical terminology, clinical findings, and documentation requirements for accurate and efficient healthcare data management.

Also known as

Kidney Cancer
Renal Cell Carcinoma

Diagnosis Snapshot

Key Facts
  • Definition : Cancerous growth in the kidney, often forming a solid tumor.
  • Clinical Signs : Blood in urine, flank pain, abdominal mass, weight loss, fatigue.
  • Common Settings : Urology clinics, oncology centers, hospitals with surgical capabilities.

Related ICD-10 Code Ranges

Complete code families applicable to AAPC C64.9 Coding
C64-C64

Malignant neoplasm of kidney

Cancers specifically affecting the kidney.

C65-C68

Malignant neoplasms of renal pelvis

Cancers of the renal pelvis, the kidney's urine collection area.

C79.0

Secondary malignant neoplasm of kidney

Cancer that has spread to the kidney from another primary site.

C00-C97

Malignant neoplasms

A broad category encompassing all malignant cancers, including kidney.

Code-Specific Guidance

Decision Tree for

Follow this step-by-step guide to choose the correct ICD-10 code.

Is the kidney neoplasm specified as malignant?

Code Comparison

Related Codes Comparison

When to use each related code

Description
Kidney Cancer
Renal Cyst
Renal Oncocytoma

Documentation Best Practices

Documentation Checklist
  • Malignant neoplasm kidney ICD-10 diagnosis code
  • Kidney cancer staging TNM documentation
  • Laterality: Left or right kidney documented
  • Histology of kidney neoplasm specified
  • Imaging evidence: CT/MRI/US results

Coding and Audit Risks

Common Risks
  • Lateralization Missing

    Unspecified laterality (right, left, or bilateral) can lead to coding errors and inaccurate treatment plans. Affects accurate staging and reimbursement.

  • Histology Mismatch

    Discrepancy between histology report and coded diagnosis can cause claims rejection and affect cancer registry data accuracy. Impacts patient care and research.

  • Stage Incompleteness

    Missing TNM staging components (tumor size, node involvement, metastasis) impacts treatment planning and accurate reimbursement. Affects quality reporting and outcomes analysis.

Mitigation Tips

Best Practices
  • Accurate ICD-10 coding (C64.-) for kidney cancer diagnosis.
  • Precise CDI of tumor site, size, and laterality.
  • Timely pathology reports for staging (TNM) & histology.
  • Regular follow-up documentation per NCCN guidelines.
  • Ensure compliance for appropriate treatment authorization.

Clinical Decision Support

Checklist
  • Verify ICD-10 C64, C65 documented: Renal malignancy code
  • Confirm laterality (right/left/bilateral kidney) noted
  • Imaging (CT/MRI/US) report supports malignancy diagnosis
  • Histopathology report confirms malignant neoplasm diagnosis

Reimbursement and Quality Metrics

Impact Summary
  • Malignant Neoplasm of Kidney reimbursement hinges on accurate ICD-10-CM (C64-C68) and CPT coding for procedures like nephrectomy, biopsy, radiation.
  • Coding quality directly impacts Case Mix Index (CMI) and hospital reimbursement for kidney cancer. Proper documentation is crucial.
  • Timely and accurate billing and coding minimizes claim denials and optimizes revenue cycle for kidney cancer treatment.
  • Quality metrics like patient survival, complications, and readmissions influence hospital rankings and value-based payments for kidney cancer care.

Streamline Your Medical Coding

Let S10.AI help you select the most accurate ICD-10 codes. Our AI-powered assistant ensures compliance and reduces coding errors.

Frequently Asked Questions

Common Questions and Answers

Q: What are the most effective current treatment strategies for localized renal cell carcinoma in elderly patients with significant comorbidities?

A: Treatment for localized renal cell carcinoma (RCC) in elderly patients with comorbidities requires careful consideration of patient-specific factors, balancing oncologic effectiveness with preservation of renal function and overall quality of life. While surgical resection (partial or radical nephrectomy) remains the standard of care for fit patients, less invasive options are increasingly utilized for those with significant comorbidities. These include thermal ablation (radiofrequency ablation, cryoablation) and active surveillance, particularly for smaller tumors. The choice depends on tumor size, location, patient overall health status, and life expectancy. Explore how recent advancements in minimally invasive surgery can offer benefits for this patient population. Consider implementing a shared decision-making approach to ensure treatment aligns with patient goals and preferences.

Q: How can I differentiate between benign renal cysts and malignant renal masses using imaging modalities like CT and MRI, and when is a renal biopsy indicated in the workup of a renal mass?

A: Differentiating benign renal cysts from malignant renal masses often relies on specific imaging characteristics on CT and MRI. Simple cysts typically appear as smooth, thin-walled, homogeneous, water-density lesions without enhancement. Complex cysts, however, may have septations, calcifications, or thicker walls, requiring further evaluation. Malignant masses often demonstrate solid components, irregular margins, and enhancement on contrast imaging. While imaging can often provide a high degree of confidence, a renal biopsy is sometimes indicated for indeterminate renal masses, particularly when the diagnosis would alter management. Learn more about the specific imaging criteria used to characterize renal masses and the role of biopsy in the diagnostic algorithm.

Quick Tips

Practical Coding Tips
  • Code C64 for kidney neoplasm
  • Laterality matters: use C64.0-C64.9
  • Document histology for accurate coding
  • Metastasis? Use M code with C64
  • Check ICD-10-CM guidelines yearly

Documentation Templates

Patient presents with complaints concerning for renal cell carcinoma (RCC), including hematuria, flank pain, and palpable abdominal mass.  Symptoms onset reported as [timeframe].  Review of systems reveals [list pertinent positive and negative findings].  Past medical history significant for [relevant comorbidities, e.g., hypertension, diabetes, smoking history].  Family history notable for [family history of cancer, specifically kidney cancer].  Physical examination reveals [objective findings, e.g., tenderness in the flank, palpable mass].  Computed tomography (CT) scan of the abdomen and pelvis demonstrates a [size] cm enhancing renal mass in the [location, e.g., upper pole of the left kidney], suggestive of renal malignancy.  Differential diagnosis includes renal cell carcinoma, renal oncocytoma, and angiomyolipoma.  Laboratory findings include [relevant lab values, e.g., elevated creatinine, anemia].  Biopsy is planned to confirm the diagnosis.  Preliminary diagnosis of malignant neoplasm of kidney (ICD-10 C64.9) is made.  Treatment options, including nephrectomy (partial or radical), targeted therapy, and immunotherapy, were discussed with the patient.  Patient will be referred to urology and oncology for further evaluation and management.  Patient education provided on kidney cancer staging, prognosis, and treatment options.  Follow-up scheduled in [timeframe] to discuss biopsy results and finalize treatment plan.  Referral to nephrology may be considered for optimization of renal function.